The BCL2A1 antibody targets the BCL-2-related protein A1 (BCL2A1), a member of the BCL-2 family of apoptosis-regulating proteins. BCL2A1. also known as Bfl-1. functions as an anti-apoptotic protein by inhibiting mitochondrial outer membrane permeabilization, thereby blocking caspase activation and cell death. It is primarily expressed in hematopoietic cells and certain cancers, where its overexpression contributes to tumor survival, chemoresistance, and immune evasion.
BCL2A1 antibodies are critical tools for studying its expression, localization, and interaction with pro-apoptotic proteins like BIM or BAX. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to investigate BCL2A1's role in cancers (e.g., lymphoma, leukemia) and inflammatory diseases. Commercially available clones (e.g., CL4883. D5Z4Z) are often validated for specificity across human, mouse, or rat samples.
Research highlights BCL2A1's clinical relevance in therapy resistance, making it a potential biomarker or therapeutic target. However, challenges remain in distinguishing BCL2A1 from other BCL-2 homologs due to structural similarities, necessitating rigorous antibody validation. Ongoing studies explore BCL2A1's regulation by NF-κB signaling and its impact on tumor microenvironments, underscoring its dual role in apoptosis and immune modulation.